Sanofi has announced Phase 2 trial results for Lunsekimig, a bispecific biologic targeting two well-known drivers of inflammation: TSLP and IL-13. While the drug achieved significant milestones in respiratory conditions, it fell short in a dermatology-focused trial.
Key findings from the clinical trials include:
-
Success in Respiratory Conditions: The drug met its primary and key secondary endpoints in patients with moderate-to-severe asthma and chronic rhinitis with nasal polyps. Treatment led to a clinically meaningful reduction in symptom flare-ups, improved lung function, and reduced the size and severity of nasal polyps.
-
Miss in Dermatology: Lunsekimig failed to reach its main objective for skin clearance compared to a placebo in an atopic dermatitis (eczema) trial. This outcome was somewhat anticipated by analysts, given the limited prior evidence of synergistic effects between TSLP and IL-13 inhibition in treating eczema.
-
Consistent Safety Profile: Across all trials, the therapy was generally well-tolerated. Rates of serious adverse events and treatment discontinuation were comparable between the treatment group and the placebo recipients.
-
Pressure for a Successor: Sanofi is under increasing pressure to identify a new flagship product to succeed its “blockbuster” Dupixent—a drug that accounted for one-third of the company’s sales last year but faces patent expiration in the U.S. in 2031.
Industry analysts project that Lunsekimig could achieve peak annual sales of approximately $3 billion based on its positioning in respiratory diseases alone. More detailed data will be presented at future medical meetings to clarify the drug’s competitive standing against existing therapies.